OPKO Health, Inc. (NASDAQ:OPK – Get Free Report) Director Richard C. Pfenniger, Jr. purchased 25,000 shares of the firm’s stock in a transaction on Monday, November 13th. The stock was acquired at an average cost of $1.30 per share, for a total transaction of $32,500.00. Following the completion of the purchase, the director now owns 300,000 shares in the company, valued at approximately $390,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
OPKO Health Stock Performance
NASDAQ OPK opened at $1.42 on Thursday. The firm has a market capitalization of $1.10 billion, a P/E ratio of -5.26 and a beta of 1.84. OPKO Health, Inc. has a 1-year low of $1.00 and a 1-year high of $2.24. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.78 and a quick ratio of 1.44. The business’s 50-day simple moving average is $1.45 and its 200-day simple moving average is $1.65.
OPKO Health (NASDAQ:OPK – Get Free Report) last released its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The firm had revenue of $178.60 million during the quarter, compared to analyst estimates of $174.78 million. OPKO Health had a negative net margin of 23.94% and a negative return on equity of 13.63%. The business’s revenue for the quarter was down .6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.11) earnings per share. Equities analysts predict that OPKO Health, Inc. will post -0.24 EPS for the current year.
Institutional Investors Weigh In On OPKO Health
Wall Street Analyst Weigh In
A number of brokerages have issued reports on OPK. HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Monday, August 7th. StockNews.com raised OPKO Health from a “sell” rating to a “hold” rating in a research note on Wednesday. Finally, Piper Sandler raised their price target on OPKO Health from $4.00 to $5.00 in a research note on Monday, August 7th.
OPKO Health Company Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
- Five stocks we like better than OPKO Health
- Bank Stocks – Best Bank Stocks to Invest In
- Buffett’s latest portfolio additions, trims, and cuts in Q3
- Dividend Tax Calculator
- 5 reasons TJX Companies will hit new highs in 2024
- What is a Secondary Public Offering? What Investors Need to Know
- Game-changing news for Ambarella puts the market in reversal
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.